Flash Buy: Eliminating Chemo Side Effects
Last week’s portfolio pick is doing well — up 25% as we speak. We look to add more to our portfolio today as a new company looks to eliminate one of the major side effects of chemotherapy.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Ray Blanco’s FDA Trader
Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.
